09.28.26 -- 6 Modeling Approaches That Make Complex Bioprocess Data Useful

Accelerate cell line development with a host engineered for high expression, streamlined clone selection, flexible gene integration, and scalable industrial performance.

New approaches to suspension cell culture and process scaling enable consistent, high-titer rAAV production. Gain insight into a clearer path to scalable manufacturing for gene therapy pipelines.

Discover how integrated immune profiling reveals biomarkers and mechanistic insights into toxicity and treatment response, driving advances in cell therapy and personalized immunotherapy strategies.

N-1 perfusion enables higher inoculum densities, faster production, and reduced costs without altering fed-batch processes. Explore a practical path to intensification for biologics manufacturers.

A rapid, integrated biologics development strategy can achieve IND readiness in as little as six months by combining parallel workflows, early risk mitigation, advanced technologies, and more.

Stable bulk cultures, made highly uniform using transposase-mediated technologies, may be the key to expediting clone selection for many biopharmaceutical applications.

See how in vitro glycoengineering uncouples glycosylation from fermentation variables, removing production compromises to safely optimize therapeutic protein yield and quality.

Review the results obtained for our proprietary HEK293T 2G7 suspension cell line for LVV production by transient transfection in serum-free, chemically-defined and animal component-free media.

Uncover an innovative serum-free method to differentiate induced pluripotent stem cells (iPSCs) into natural killer (NK) cells, offering scalable solutions for immunotherapy with enhanced cytotoxic potential.

Run-to-run AAV titer variability can jeopardize production. Controlling incubation timing, DNA input, and media conditions improves yield and batch consistency.

Delve into how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.